Zhang KYJ, Milburn MV, Artis DR. Scaffold-based drug discovery. Struct Based Drug Discov. 2007. p. 129–53. https://doi.org/10.1007/1-4020-4407-0_6.

Hu Y, Stumpfe D, Bajorath J. Computational exploration of molecular scaffolds in medicinal chemistry. J Med Chem. 2016;59:4062–76. https://doi.org/10.1021/acs.jmedchem.5b01746.

Article  CAS  PubMed  Google Scholar 

Doak BC, Norton RS, Scanlon MJ. The ways and means of fragment-based drug design. Pharm Ther. 2016;167:28–37. https://doi.org/10.1016/j.pharmthera.2016.07.003.

Article  CAS  Google Scholar 

Mello JDFRE, Gomes RA, Vital-Fujii DG, Ferreira GM, Trossini GHG. Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. Chem Biol Drug Des. 2017;90:1067–78. https://doi.org/10.1111/cbdd.13030.

Article  CAS  PubMed  Google Scholar 

Bon M, Bilsland A, Bower J, McAulay K. Fragment‐based drug discovery—the importance of high‐quality molecule libraries. Mol Oncol. 2022;16:3761–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q. Application of fragment-based drug discovery to versatile targets. Front Mol Biosci. 2020;7:180.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov. 2016;15:605–19.

Article  CAS  PubMed  Google Scholar 

Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat Chem. 2009;1:187–92.

Article  CAS  PubMed  Google Scholar 

Jhoti H, Leach AR, Zhang KYJ, Milburn MV, DR Artis. Scaffold-based drug discovery. Struct Based Drug Discov. 2007. p. 129–53. https://doi.org/10.1007/1-4020-4407-0_6.

Gizzo S, Saccardi C, Patrelli TS, Berretta R, Capobianco G, Gangi SD, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013;68:467–81. https://doi.org/10.1097/OGX.0b013e31828baef9.

Article  PubMed  Google Scholar 

Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: Synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem. 2011;46:4853–8. https://doi.org/10.1016/j.ejmech.2011.07.050.

Article  CAS  PubMed  Google Scholar 

Mehrabi F, Pourshojaei Y, Moradi A, Sharifzadeh M, Khosravani L, Sabourian R, et al. Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain. Future Med Chem. 2017;9:659–71. https://doi.org/10.4155/fmc-2016-0237.

Article  CAS  PubMed  Google Scholar 

Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis. 2016;16:61–69. https://doi.org/10.1016/S1473-3099(15)00320-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Florvaag E, Johansson SGO. The Pholcodine case. cough medicines, IgE-sensitization, and anaphylaxis: a devious connection. World Allergy Organ J. 2012;5:73–78. https://doi.org/10.1097/WOX.0b013e318261eccc.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh RK, Singh AK, Singh AK. Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands. Eur J Med Chem. 2016. https://doi.org/10.1016/j.molstruc.2016.09.072.This.

Jameera Begam A, Jubie S, Nanjan MJ. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem. 2017;71:257–74. https://doi.org/10.1016/j.bioorg.2017.02.011.

Article  CAS  PubMed  Google Scholar 

Kulkarni J, Butler S, Riecher-Rössler A. Estrogens and SERMS as adjunctive treatments for schizophrenia. Front Neuroendocrinol. 2019;53. https://doi.org/10.1016/j.yfrne.2019.03.002.

Lewis-Wambi J, Jordan VC. Raloxifene. Comprehensive Medicinal Chemistry II (Elsevier, 2007), 103–21. https://doi.org/10.1016/B0-08-045044-X/00294-7.

Mukherjee S, Nagar S, Mullick S, Mukherjee A, Saha A. Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches. J Mol Graph Model. 2008;26:884–92. https://doi.org/10.1016/j.jmgm.2007.06.003.

Article  CAS  PubMed  Google Scholar 

Jones CD, Goettel ME. Process for preparing 3-(4-aminoethoxybenzoyl) benzo [b] thiophenes, 1982.

Ariazi EA, Craig Jordan V. Estrogen receptors as therapeutic targets in breast cancer. Nucl Recept Drug Targets. 2008;39:127–99. https://doi.org/10.1002/9783527623297.ch5.

Article  CAS  Google Scholar 

Cosman F, Lindsay R. Selective estrogen receptor modulators. Treatment of the Postmenopausal Woman (Elsevier, 2007), pp. 837–45. https://doi.org/10.1016/B978-012369443-0/50073-9.

Jatoi I, Kaufmann M. Management of breast diseases (Springer, 2016).

Bailey HH, Heckman-Stoddard BM, Fabian CJ, Kimler BF, Zalles CM, Phillips TA, et al. Clinical trial of acolbifene in premenopausal women at high risk for breast cancer. Cancer Prev Res. 2015;8:1146–55. https://doi.org/10.1158/1940-6207.CAPR-15-0109.

Article  CAS  Google Scholar 

Degregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014;90:82–93. https://doi.org/10.1016/J.STEROIDS.2014.07.012.

Article  CAS  PubMed  Google Scholar 

Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast cancer Res Treat. 2002;73:161–75.

Article  CAS  PubMed  Google Scholar 

NCT03781063, Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation. https://clinicaltrials.gov/show/NCT03781063 2018.

Gara R, Sundram V, Chauhan S, Jaggi M. Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem. 2013. https://doi.org/10.2174/09298673113209990197.

Pati T, Chanania K, Marandi S, Hansa J. Ormeloxifene-Looking beyond contraception. J Life Health. 2017;8:17–20. https://doi.org/10.4103/jmh.JMH_71_16.

Article  Google Scholar 

Hu H. Different Strategies to Improve Drug Tissue Selectivity for Better Efficacy/Toxicity Profile (Doctoral dissertation). 2022.

SWJ Lamberts & AWVANDEN Beld, Chapter 27—Endocrinology and aging. Williams Textbook Endocrinol. 2018:1234–51. https://doi.org/10.1016/B978-0-323-29738-7.00027-7.

Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an estrogen receptor targeted therapy: from bench to bedside. Endocrinology. 2021;162.

Pourshojaei Y, Gouranourimi A, Hekmat S, Asadipour A, Rahmani-Nezhad S, Moradi A, et al. Design, synthesis and anticholinesterase activity of novel benzylidenechroman-4-ones bearing cyclic amine side chain. Eur J Med Chem. 2015;97:181–9.

Article  CAS  PubMed  Google Scholar 

Liu Q-H, Wu J-J, Li F, Cai P, Yang X-L, Kong L-Y, et al. Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer’s disease. MedChemComm. 2017;8:1459–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pourshojaei Y, Abiri A, Eskandari K, Haghighijoo Z, Edraki N, Asadipour A. Phenoxyethyl piperidine/morpholine derivatives as PAS and CAS inhibitors of cholinesterases: insights for future drug design. Sci Rep. 2019;9:19855. https://doi.org/10.1038/s41598-019-56463-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenthal PJ. Artefenomel: a promising new antimalarial drug. Lancet Infect Dis. 2015;3099:5–6. https://doi.org/10.1016/S1473-3099(15)00343-6.

Article  Google Scholar 

Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin action and resistance in plasmodium falciparum. Trends Parasitol. 2016;32:682–96. https://doi.org/10.1016/j.pt.2016.05.010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN. et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci. 2011;108:4400–5. https://doi.org/10.1073/pnas.1015762108.

Article  PubMed  PubMed Central  Google Scholar 

Kim S, Im S-A, Min A, Lee M, Jang H, Lee K-H, et al. Antitumor effect of KX-01, a novel Src and tubulin inhibitor, in triple negative breast cancer cells. Cancer Res. 2014;74:5479.

Article  Google Scholar 

BU Y, Smolinski M, Qu J, Kazim L, Gelman I, Dyster L, et al. Mechanism of action KX01 (KX2-391), a novel tubulin polymerization and Src signaling inhibitor proceeding to Phase II clinical trials. Cancer Res. 2010;70:2487.

Article  Google Scholar 

Brusch AM, Clarke RC, Platt PR, Phillips EJ. Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis. Br J Clin Pharmacol. 2014;78:14–23.

Article  CAS  PubMed  Google Scholar 

Anbalagan M, Sheng M, Fleischer B, Zhang Y, Gao Y, Hoang V, et al. Dual Src kinase/pretubulin inhibitor KX-01, sensitizes ERα-negative breast cancers to tamoxifen through ERα reexpression. Mol Cancer Res. 2017;15:1491–502. https://doi.org/10.1158/1541-7786.MCR-16-0297-T

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerostamoulos D. Opioids. Wiley Encyclopedia of Forensic Science. Chichester UK: John Wiley & Sons, Ltd, 2009. https://doi.org/10.1002/9780470061589.fsa422.

Jończyk J, Malawska B, Bajda M. Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification. PLoS ONE. 2017;12. https://doi.org/10.1371/journal.pone.0186108.

Syed YY. Pitolisant: first global approval. Drugs. 2016;76:1313–8. https://doi.org/10.1007/s40265-016-0620-1.

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Gumbrell LA, Evans TRJ, Coleman RE, Smith IE, Twelves CJ, et al. A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol. 2004;53:341–8. https://doi.org/10.1007/s00280-003-0733-6.